Itonis Pharmaceuticals to Trademark Emesyl Nausea Relief Remedy
LAGUNA HILLS, CA--(Marketwired - Oct 24, 2013) - Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam® cold remedy, are pleased to announce that the Company has applied to the USPTO to trademark its Emesyl brand for its homeopathic pharmaceutical nausea relief remedy. The Company's application has been assigned Serial No. 86099093.
Previously, the Company announced its first order for the Emesyl product, and that it obtained a labeler's code for the Company's National Drug Code (NDC) number. Now, trademark protection is another step towards the release and distribution of the Emesyl nausea relief product.
"We at the Company are excited with our progress towards bringing our new homeopathic nausea remedy to market, and obtaining proprietary rights protections brings us closer to that goal," says Mark Cheung, the Company's CEO.
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
